Empowered Funds LLC Sells 10,120 Shares of Cencora, Inc. (NYSE:COR)

Empowered Funds LLC reduced its stake in Cencora, Inc. (NYSE:COR - Free Report) by 13.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 66,184 shares of the company's stock after selling 10,120 shares during the period. Empowered Funds LLC's holdings in Cencora were worth $14,870,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of COR. Dynamic Advisor Solutions LLC increased its holdings in Cencora by 15.2% in the 3rd quarter. Dynamic Advisor Solutions LLC now owns 1,166 shares of the company's stock valued at $262,000 after acquiring an additional 154 shares during the last quarter. LVW Advisors LLC increased its holdings in Cencora by 14.2% in the 3rd quarter. LVW Advisors LLC now owns 3,666 shares of the company's stock valued at $825,000 after acquiring an additional 456 shares during the last quarter. Iowa State Bank bought a new stake in Cencora in the 3rd quarter valued at $1,390,000. Livforsakringsbolaget Skandia Omsesidigt increased its holdings in Cencora by 33.7% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 27,375 shares of the company's stock valued at $6,160,000 after acquiring an additional 6,900 shares during the last quarter. Finally, Valeo Financial Advisors LLC increased its holdings in Cencora by 5.0% in the 3rd quarter. Valeo Financial Advisors LLC now owns 1,645 shares of the company's stock valued at $370,000 after acquiring an additional 79 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Trading Down 1.3 %

Shares of COR stock traded down $3.20 during trading hours on Wednesday, reaching $243.55. 2,548,535 shares of the stock were exchanged, compared to its average volume of 1,514,966. The firm has a market capitalization of $47.07 billion, a price-to-earnings ratio of 34.64, a price-to-earnings-growth ratio of 1.49 and a beta of 0.49. The company has a current ratio of 0.92, a quick ratio of 0.53 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $262.26. The company's 50-day moving average price is $238.70 and its 200-day moving average price is $237.21.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, equities analysts anticipate that Cencora, Inc. will post 15.36 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be given a $0.55 dividend. The ex-dividend date is Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.90%. Cencora's dividend payout ratio (DPR) is 31.29%.

Wall Street Analysts Forecast Growth

COR has been the subject of a number of recent research reports. Robert W. Baird lifted their price objective on shares of Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. Mizuho initiated coverage on shares of Cencora in a research note on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price objective for the company. Evercore ISI lifted their price objective on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. UBS Group lifted their price objective on shares of Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Finally, Wells Fargo & Company lifted their price objective on shares of Cencora from $237.00 to $251.00 and gave the stock an "equal weight" rating in a research note on Wednesday, January 29th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, Cencora has an average rating of "Moderate Buy" and an average price target of $277.90.

Insider Buying and Selling at Cencora

In other news, EVP Silvana Battaglia sold 1,678 shares of the business's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 50,000 shares of the business's stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the sale, the chairman now owns 326,557 shares of the company's stock, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 73,187 shares of company stock valued at $17,790,912 in the last three months. Company insiders own 10.80% of the company's stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.